Background: In Italy, there is scarce evidence on the epidemiological and economic burden induced by primary antibody deficiencies.
Objective: The aim of this study was to elaborate the available epidemiological and cost data in order to estimate the annual expenditure induced by the management of patients affected by the common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA) requiring immunoglobulin (Ig) replacement therapy.
Methods: A probabilistic cost-of-illness model was developed to estimate the number of patients with CVID and XLA, and the economic burden associated with their therapy in terms of direct or indirect costs. A systematic literature review was carried out to reveal both epidemiological and economic data. Furthermore, a probabilistic sensitivity analysis with 5000 Monte Carlo simulations was performed.
Results: The epidemiological model allowed us to estimate the number of prevalent patients affected by XLA and CVID in Italy in 2017, corresponding to 1885 (95% confidence interval [CI] 944-3145) and 133 (95% CI 115-152) patients, respectively. The estimated total expenditure for the treatment and management of patients with CVID and XLA requiring Ig replacement therapy amounts to €42.68 million (95% CI €14.38-€86.1 million).
Conclusions: This information provides a comprehensive perspective of the economic issues, and facilitates better-informed public health decision making, in the management of CVID and XLA in Italy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40261-018-0688-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
Front Immunol
May 2024
Department of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands.
Purpose: Previous studies have demonstrated that the majority of patients with an inborn error of immunity (IEI) develop a spike (S)-specific IgG antibody and T-cell response after two doses of the mRNA-1273 COVID-19 vaccine, but little is known about the response to a booster vaccination. We studied the immune responses 8 weeks after booster vaccination with mRNA-based COVID-19 vaccines in 171 IEI patients. Moreover, we evaluated the clinical outcomes in these patients one year after the start of the Dutch COVID-19 vaccination campaign.
View Article and Find Full Text PDFFollow-up of immune response in patients with common variable immunodeficiency following SARS-CoV-2 vaccination.
Clin Exp Immunol
August 2024
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
The COVID-19 pandemic highlighted the importance of effective vaccination strategies in controlling the spread of infectious diseases. SARS-CoV-2 vaccine has demonstrated high efficacy in preventing COVID-19 infection in the general population. However, the efficacy of this vaccine in patients with predominantly antibody deficiencies, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), should be closely monitored.
View Article and Find Full Text PDFPulmonary Computed Tomography Screening Frequency in Primary Antibody Deficiency.
J Allergy Clin Immunol Pract
April 2024
Department of Internal Medicine, Infectious Diseases, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address:
Background: Patients with primary antibody deficiency (PAD) frequently suffer from pulmonary complications, associated with severe morbidity and mortality. Hence, regular pulmonary screening by computed tomography (CT) scanning is advised. However, predictive risk factors for pulmonary morbidity are lacking.
View Article and Find Full Text PDFCellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
Front Immunol
October 2023
Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland.
Article Synopsis
- * This study involved 57 adult PAD patients receiving immunoglobulin therapy, with most vaccinated using the Pfizer-BioNTech mRNA vaccine, and evaluated their immune response through T-cell activity following a booster dose.
- * Results indicated that vaccinated PAD patients exhibited a significant increase in T-cell response and higher levels of anti-SARS-CoV-2 antibodies, especially in those with common variable immunodeficiency (CVID) compared to other types of PAD, although these antibody levels were lower compared to other groups
Chronic Diarrhea with Villous Blunting of the Small Intestine Under Capsule Endoscopy in Common Variable Immunodeficiency and X-Linked Agammaglobulinemia: A Case Series.
J Asthma Allergy
September 2023
Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China.
Introduction: Primary immunodeficiencies (PIDs) are a heterogeneous group of disorders, common variable immunodeficiency disorder (CVID) and X-linked agammaglobulinemia (XLA) are PIDs related to B-cell defect, characterized by reduced levels of immunoglobulins and immune dysregulation. Infections are the most common clinical manifestations, while underlying autoimmune and inflammatory conditions are present in some patients with CVID and XLA, leading to clinical misdiagnosis and diagnostic delay. Chronic diarrhea in patients with CVID and XLA, particularly complicated malabsorption and protein-energy malnutrition, is responsible for poor prognostic outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!